Logo image of ALVO

ALVOTECH SA (ALVO) Stock Fundamental Analysis

NASDAQ:ALVO - Nasdaq - LU2458332611 - Common Stock - Currency: USD

8.34  -0.02 (-0.24%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ALVO. ALVO was compared to 568 industry peers in the Biotechnology industry. ALVO may be in some trouble as it scores bad on both profitability and health. ALVO is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

ALVO had negative earnings in the past year.
In the past year ALVO has reported a negative cash flow from operations.
ALVO had negative earnings in each of the past 5 years.
ALVO had a negative operating cash flow in each of the past 5 years.
ALVO Yearly Net Income VS EBIT VS OCF VS FCFALVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -200M -400M

1.2 Ratios

ALVO has a Return On Assets of -18.98%. This is in the better half of the industry: ALVO outperforms 79.58% of its industry peers.
ALVO has a Return On Invested Capital of 5.35%. This is amongst the best in the industry. ALVO outperforms 94.01% of its industry peers.
Industry RankSector Rank
ROA -18.98%
ROE N/A
ROIC 5.35%
ROA(3y)-46.35%
ROA(5y)-38.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALVO Yearly ROA, ROE, ROICALVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

ALVO has a Operating Margin of 14.16%. This is amongst the best in the industry. ALVO outperforms 95.25% of its industry peers.
Looking at the Gross Margin, with a value of 62.33%, ALVO is in the better half of the industry, outperforming 78.52% of the companies in the same industry.
Industry RankSector Rank
OM 14.16%
PM (TTM) N/A
GM 62.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALVO Yearly Profit, Operating, Gross MarginsALVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ALVO is destroying value.
The number of shares outstanding for ALVO has been increased compared to 1 year ago.
Compared to 1 year ago, ALVO has an improved debt to assets ratio.
ALVO Yearly Shares OutstandingALVO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100M 200M 300M
ALVO Yearly Total Debt VS Total AssetsALVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -1.00, we must say that ALVO is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.00, ALVO is in the better half of the industry, outperforming 60.56% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1
ROIC/WACC0.73
WACC7.3%
ALVO Yearly LT Debt VS Equity VS FCFALVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

ALVO has a Current Ratio of 2.35. This indicates that ALVO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ALVO (2.35) is worse than 71.83% of its industry peers.
ALVO has a Quick Ratio of 1.69. This is a normal value and indicates that ALVO is financially healthy and should not expect problems in meeting its short term obligations.
ALVO has a worse Quick ratio (1.69) than 78.87% of its industry peers.
Industry RankSector Rank
Current Ratio 2.35
Quick Ratio 1.69
ALVO Yearly Current Assets VS Current LiabilitesALVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

7

3. Growth

3.1 Past

ALVO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 64.39%, which is quite impressive.
ALVO shows a strong growth in Revenue. In the last year, the Revenue has grown by 426.84%.
Measured over the past years, ALVO shows a very strong growth in Revenue. The Revenue has been growing by 42.86% on average per year.
EPS 1Y (TTM)64.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)426.84%
Revenue growth 3Y131.44%
Revenue growth 5Y42.86%
Sales Q2Q%0%

3.2 Future

The Earnings Per Share is expected to grow by 44.08% on average over the next years. This is a very strong growth
Based on estimates for the next years, ALVO will show a very strong growth in Revenue. The Revenue will grow by 43.33% on average per year.
EPS Next Y104.4%
EPS Next 2Y59.35%
EPS Next 3Y44.08%
EPS Next 5YN/A
Revenue Next Year42.14%
Revenue Next 2Y43.93%
Revenue Next 3Y43.33%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ALVO Yearly Revenue VS EstimatesALVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2030 500M 1B 1.5B
ALVO Yearly EPS VS EstimatesALVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 -1

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALVO. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 17.77, which indicates a rather expensive current valuation of ALVO.
94.54% of the companies in the same industry are more expensive than ALVO, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.44, ALVO is valued at the same level.
Industry RankSector Rank
PE N/A
Fwd PE 17.77
ALVO Price Earnings VS Forward Price EarningsALVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ALVO is valued cheaply inside the industry as 93.84% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 36.28
ALVO Per share dataALVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ALVO's earnings are expected to grow with 44.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y59.35%
EPS Next 3Y44.08%

More info and screens

0

5. Dividend

5.1 Amount

ALVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALVOTECH SA

NASDAQ:ALVO (4/24/2025, 2:40:08 PM)

8.34

-0.02 (-0.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26 2025-03-26/amc
Earnings (Next)05-07 2025-05-07/amc
Inst Owners5.83%
Inst Owner ChangeN/A
Ins Owners0.61%
Ins Owner ChangeN/A
Market Cap2.52B
Analysts78
Price Target18.87 (126.26%)
Short Float %0.5%
Short Ratio3.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.98%
Min EPS beat(2)38.96%
Max EPS beat(2)64.99%
EPS beat(4)3
Avg EPS beat(4)2040.9%
Min EPS beat(4)-990.69%
Max EPS beat(4)9050.33%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)21.9%
Min Revenue beat(2)13.45%
Max Revenue beat(2)30.36%
Revenue beat(4)2
Avg Revenue beat(4)5.53%
Min Revenue beat(4)-19.62%
Max Revenue beat(4)30.36%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.45%
PT rev (3m)-8.64%
EPS NQ rev (1m)-711.11%
EPS NQ rev (3m)-315.69%
EPS NY rev (1m)-84.88%
EPS NY rev (3m)-76.92%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)-2.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 17.77
P/S 5.12
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 36.28
EPS(TTM)-0.87
EYN/A
EPS(NY)0.47
Fwd EY5.63%
FCF(TTM)-0.97
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS1.63
BVpS-1.37
TBVpS-1.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.98%
ROE N/A
ROCE 6.77%
ROIC 5.35%
ROICexc 5.63%
ROICexgc 5.82%
OM 14.16%
PM (TTM) N/A
GM 62.33%
FCFM N/A
ROA(3y)-46.35%
ROA(5y)-38.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 11.37
Cap/Depr 182.1%
Cap/Sales 11.59%
Interest Coverage 1.27
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.35
Quick Ratio 1.69
Altman-Z -1
F-Score5
WACC7.3%
ROIC/WACC0.73
Cap/Depr(3y)204.72%
Cap/Depr(5y)182.09%
Cap/Sales(3y)39.66%
Cap/Sales(5y)47.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y104.4%
EPS Next 2Y59.35%
EPS Next 3Y44.08%
EPS Next 5YN/A
Revenue 1Y (TTM)426.84%
Revenue growth 3Y131.44%
Revenue growth 5Y42.86%
Sales Q2Q%0%
Revenue Next Year42.14%
Revenue Next 2Y43.93%
Revenue Next 3Y43.33%
Revenue Next 5YN/A
EBIT growth 1Y119.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year161.54%
EBIT Next 3Y85.16%
EBIT Next 5YN/A
FCF growth 1Y18.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.13%
OCF growth 3YN/A
OCF growth 5YN/A